News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,082 Results
Type
Article (40870)
Company Profile (267)
Press Release (679935)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204652)
Career Advice (2022)
Deals (35531)
Drug Delivery (110)
Drug Development (81369)
Employer Resources (173)
FDA (16402)
Job Trends (14941)
News (346346)
Policy (32721)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (32)
Adcomms (24)
Allergies (137)
Alliances (49575)
ALS (167)
Alzheimer's disease (1658)
Antibody-drug conjugate (ADC) (306)
Approvals (16667)
Artificial intelligence (500)
Autoimmune disease (143)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (631)
Cancer (4750)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (728)
Cervical cancer (36)
Clinical research (69485)
Collaboration (1666)
Company closure (4)
Compensation (1138)
Complete response letters (52)
COVID-19 (2707)
CRISPR (87)
C-suite (810)
Cystic fibrosis (143)
Data (6144)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (495)
Diagnostics (6669)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (241)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (225)
Earnings (90034)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117170)
Executive appointments (958)
FDA (19475)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1444)
Gene editing (191)
Generative AI (42)
Gene therapy (581)
GLP-1 (962)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18867)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (103)
Infectious disease (2965)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16638)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (639)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (776)
MASH (161)
Medical device (13753)
Medtech (13805)
Mergers & acquisitions (19950)
Metabolic disorders (1250)
Multiple sclerosis (155)
NASH (16)
Neurodegenerative disease (307)
Neuropsychiatric disorders (86)
Neuroscience (2864)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4508)
Now hiring (65)
Obesity (586)
Opinion (256)
Ovarian cancer (164)
Pain (195)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (469)
Peanut (55)
People (58804)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21664)
Phase 2 (30580)
Phase 3 (22788)
Pipeline (5071)
Policy (278)
Postmarket research (2564)
Preclinical (9190)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (813)
Real estate (5953)
Recruiting (69)
Regulatory (24410)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (983)
Venture capital (86)
Weight loss (376)
Women's health (87)
Worklife (18)
Date
Today (14)
Last 7 days (591)
Last 30 days (2202)
Last 365 days (29783)
2026 (2811)
2025 (30173)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39184)
Australia (6404)
California (11153)
Canada (3249)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84413)
Florida (1660)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (850)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7985)
Michigan (319)
Minnesota (621)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2965)
New Mexico (28)
New York (2939)
North Carolina (1433)
North Dakota (8)
Northern California (5435)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4339)
Tennessee (172)
Texas (1718)
United States (39529)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,082 Results for "neomorph inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
February 4, 2026
·
2 min read
Deals
AbbVie Teams Up With Neomorph for Molecular Glue Collab Worth up to $1.64B
Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
January 23, 2025
·
1 min read
·
Annalee Armstrong
Business
Novo Inks Potential $1.46B Deal to Tap Neomorph’s Molecular Glue Platform
Under the collaboration and licensing agreement, Novo Nordisk and Neomorph are looking to discover, develop and commercialize novel molecular glue degraders for cardiometabolic and rare diseases.
February 27, 2024
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
January 23, 2025
·
2 min read
Business
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.
February 26, 2024
·
2 min read
Press Releases
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer
January 14, 2025
·
3 min read
Press Releases
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024
·
5 min read
Business
Neomorph, Inc. Announces Appointment of Chief Financial Officer
Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets,’ announced the appointment of Bell Zhong as the company’s Chief Financial Officer.
September 7, 2022
·
3 min read
News
Neomorph Announces Appointment of Dr. Peter Lebowitz, M.D., Ph.D. to its Board of Directors
August 20, 2024
·
2 min read
Biotech Beach
Neomorph, Inc. to Participate in Upcoming Guggenheim Healthcare Talks – Targeted Protein Degradation Day
Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it will participate in an upcoming virtual investor conference.
March 10, 2022
·
1 min read
1 of 72,109
Next
